ALTO-207 in Adults With Treatment-resistant Depression (TRD)
Trial details
- Registry ID
- NCT07553637
- Drugs studied
- ALTO-207
TrialRedline tracks 10 clinical trials sponsored by Alto Neuroscience: 10 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| ALTO-207 in Adults With Treatment-resistant Depression (TRD)NCT07553637 | ALTO-207 | Recruiting | 2027-11Estimated |
| ALTO-100 in Bipolar Disorder With Depression (BD-D)NCT06656416 | ALTO-100 | Recruiting | 2027-09Estimated |
| Study of ALTO-300 in MDDNCT05922878 | ALTO-300 | Recruiting | 2026-12Estimated |
| Study of ALTO-101 in Patients With SchizophreniaNCT06502964 | ALTO-101, ALTO-101 Transdermal Delivery System | Recruiting | 2026-02Estimated |
| PD, PK, and Safety of ALTO-203 in Patients With MDDNCT06391593 | ALTO-203 25 μg, ALTO-203 75 μg | Completed | 2025-04-14Actual |
| Phase 2b Study of ALTO-100 in MDDNCT05712187 | ALTO-100 | Completed | 2024-09-05Actual |
| ALTO-300 in DepressionNCT05118750 | ALTO-300 oral (PO) tablet | Completed | 2023-05-05Actual |
| ALTO-300 in Depression (ALTO-300-004)NCT05157945 | ALTO-300 PO Tablet | Completed | 2023-04-26Actual |
| Pilot Decentralized TrialNCT05419869 | ALTO-100 PO Tablet | Completed | 2023-01-13Actual |
| ALTO-100 in MDD and/or PTSDNCT05117632 | ALTO-100 PO tablet | Completed | 2022-12-01Actual |
Names as written in the registry records.
NCT05922878 · Alto Neuroscience
Before: 321 participants (planned). After: 325 participants (planned).
NCT06656416 · Alto Neuroscience
Before: Aug 2026. After: Sep 2027.
NCT06502964 · Alto Neuroscience
Before: Oct 2025. After: Feb 2026.